Selected article for: "effective vaccine and human human transmission"
Author: Banerjee, Arinjay; Baid, Kaushal; Mossman, Karen
Title: Molecular Pathogenesis of Middle East Respiratory Syndrome (MERS) Coronavirus
  • Cord-id: bftsmcl4
  • Document date: 2019_7_5
    • ID: bftsmcl4
    Snippet: PURPOSE OF REVIEW: Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 and is listed in the World Health Organization’s blueprint of priority diseases that need immediate research. Camels are reservoirs of this virus, and the virus spills over into humans through direct contact with camels. Human-to-human transmission and travel-associated cases have been identified as well. Limited studies have characterized the molecular pathogenesis of MERS-CoV. Most studies have used ec
    Document: PURPOSE OF REVIEW: Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 and is listed in the World Health Organization’s blueprint of priority diseases that need immediate research. Camels are reservoirs of this virus, and the virus spills over into humans through direct contact with camels. Human-to-human transmission and travel-associated cases have been identified as well. Limited studies have characterized the molecular pathogenesis of MERS-CoV. Most studies have used ectopic expression of viral proteins to characterize MERS-CoV and its ability to modulate antiviral responses in human cells. Studies with live virus are limited, largely due to the requirement of high containment laboratories. In this review, we have summarized current studies on MERS-CoV molecular pathogenesis and have mentioned some recent strategies that are being developed to control MERS-CoV infection. RECENT FINDINGS: Multiple antiviral molecules with the potential to inhibit MERS-CoV infection by disrupting virus-receptor interactions are being developed and tested. Although human vaccine candidates are still being developed, a candidate camel vaccine is being tested for efficacy. Combination of supportive treatment with interferon and antivirals is also being explored. SUMMARY: New antiviral molecules that inhibit MERS-CoV and host cell receptor interaction may become available in the future. Additional studies are required to identify and characterize the pathogenesis of MERS-CoV EMC/2012 and other circulating strains. An effective MERS-CoV vaccine, for humans and/or camels, along with an efficient combination antiviral therapy may help us prevent future MERS cases.

    Search related documents:
    Co phrase search for related documents
    • accessory protein and acid inducible: 1
    • accessory protein and acid inducible gene: 1
    • accessory protein and activator signal transducer: 1, 2, 3
    • accessory protein and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acid dependent and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8
    • acid inducible and activator signal transducer: 1
    • acid inducible and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acid inducible gene and activator signal transducer: 1
    • acid inducible gene and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acid sensing and acute respiratory syndrome: 1, 2, 3, 4
    • activator signal transducer and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and adaptive mers cov immune response: 1, 2, 3
    • acute respiratory syndrome and additional strategy: 1, 2
    • acute respiratory syndrome and long intensive: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and long intensive care unit: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome and long intensive care unit stay: 1, 2
    • acute respiratory syndrome and long strand: 1, 2